Avid Bioservices reported strong Q4 2022 results, marked by $31 million in revenue and a record-high backlog of $153 million. The company's facilities and service expansions are progressing as planned, with new cell and gene therapy suites now operational. Revenue guidance for fiscal year 2023 is projected to be between $140 and $145 million.